Company profile
Aktis Oncology
Expanding the breakthrough potential of targeted radiopharmaceuticals to large cancer patient populations.
- Industry
- Biotechnology Research
- Employees
- 101
Aktis Oncology company summary
Aktis Oncology is a company in the Biotechnology Research industry. On LinkedIn the company has around 101 employees.
What technology does Aktis Oncology use?
No technologies detected yet. Warmrank rechecks company websites on a rolling basis.
About Aktis Oncology
Aktis Oncology (Nasdaq: AKTS) is a clinical-stage oncology company focused on expanding the breakthrough potential of targeted radiopharmaceuticals to large patient populations, including those not addressed by existing platform technologies. The company has developed a proprietary miniprotein radioconjugate platform designed to selectively deliver the tumor-killing properties of radioisotopes to targeted tumors, while being rapidly cleared from normal organs and tissues to minimize systemic radiation exposure. Aktis’ most advanced pipeline program targets Nectin-4, a miniprotein radioconjugate with multi-indication potential across multiple tumor types. The company also maintains a strategic collaboration with Eli Lilly and Company to develop novel anticancer radiopharmaceuticals for targets outside of Aktis’ proprietary pipeline.
Compare companies similar to Aktis Oncology
More companies in Biotechnology Research.
| Company | Industry | Employees | Founded | Headquarters |
|---|---|---|---|---|
Aktis Oncology aktisoncology.com | Biotechnology Research | 101 | - | - |
 Thermo Fisher Scientific thermofisher.com | Biotechnology Research | 100,779 | - | Waltham, MA |
 Amgen amgen.com | Biotechnology Research | 41,028 | 1980 | Thousand Oaks, CA |
 Biogen biogen.com | Biotechnology Research | 7,742 | - | Cambridge, MA |
 Biocon biocon.com | Biotechnology Research | 11,902 | - | Bangalore, Karnataka |
| Biotechnology Research | 28,679 | - | Bethesda, MD | |
 Genentech gene.com | Biotechnology Research | 18,296 | 1976 | South San Francisco, California |
 Eurofins eurofins.com | Biotechnology Research | 24,928 | - | Luxembourg, Luxembourg |
 Gilead Sciences gilead.com | Biotechnology Research | 14,743 | - | Foster City, CA |
 Syneos Health syneoshealth.com | Biotechnology Research | 23,772 | - | Morrisville, NC |
 Moderna modernatx.com | Biotechnology Research | 6,238 | 2010 | Cambridge, Massachusetts |
Frequently asked questions about Aktis Oncology
What does Aktis Oncology do?
Aktis Oncology (Nasdaq: AKTS) is a clinical-stage oncology company focused on expanding the breakthrough potential of targeted radiopharmaceuticals to large patient populations, including those not addressed by existing platform technologies. The company has developed a proprietary miniprotein radioconjugate platform designed to selectively deliver the tumor-killing properties of radioisotopes to targeted tumors, while being rapidly cleared from normal organs and tissues to minimize systemic radiation exposure. Aktis’ most advanced pipeline program targets Nectin-4, a miniprotein radioconjugate with multi-indication potential across multiple tumor types. The company also maintains a strategic collaboration with Eli Lilly and Company to develop novel anticancer radiopharmaceuticals for targets outside of Aktis’ proprietary pipeline.
How many employees does Aktis Oncology have?
Aktis Oncology has around 101 employees on LinkedIn.
Build a lead list from companies like Aktis Oncology
Describe your ICP or import a CSV. Warmrank finds matching companies, enriches contacts with verified emails, and tracks every lead.